Skin cancer: More than skin deep

Gulf Coast Dermatology, Hudson, Florida, USA.
The Nurse practitioner 04/2009; 34(4):20-7; quiz 27-8. DOI: 10.1097/01.NPR.0000348317.53612.18
Source: PubMed


To provide the wound care practitioner with an updated overview of the epidemiology, clinical presentation, treatment, and prevention of skin cancer.

Target audience:
This continuing education activity is intended for physicians and nurses with an interest in skin and wound care.

After participating in this educational activity, the participant should be better able to: 1. Describe the epidemiology, pathophysiology, and clinical presentation of skin cancer. 2. Discuss the diagnosis, management, and prevention of skin cancer.

0 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The TP53 gene has an important role in the protection of cells from DNA damage due to UV exposure, and sequence variation in the gene may alter skin cancer susceptibility. To examine the association between the TP53 Arg72Pro polymorphism and skin cancer risk, we undertook a meta-analysis of 15 case-control studies involving 6,362 subjects. The quality of the studies was assessed according to a predefined scale. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were assessed for association using a random-effects model. Overall, no evidence of association was observed between TP53 genotypes and the risk of skin cancer in any genetic model (Arg/Arg vs. Pro/Pro: OR=1.05, 95% CI: 0.71-1.55; Arg/Pro vs. Pro/Pro: OR=0.92, 95% CI: 0.68-1.24; Arg/Arg+Arg/Pro vs. Pro/Pro: OR=0.97, 95% CI: 0.70-1.35; Arg/Arg vs. Arg/Pro+Pro/Pro: OR=1.15, 95% CI: 0.91-1.46). Stratified analyses according to ethnicity and quality score of the studies also detected no significant association in any subgroup. Furthermore, no effect of this polymorphism on subtype of skin cancer, such as melanoma, squamous cell carcinoma, and basal cell carcinoma, was observed. In conclusion, this meta-analysis suggests that the TP53 Arg72Pro polymorphism may have little involvement in skin cancer susceptibility.
    Journal of Investigative Dermatology 01/2011; 131(1):220-8. DOI:10.1038/jid.2010.270 · 7.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The xeroderma pigmentosum complementation group C gene (XPC) has been identified as important for repairing UV-related DNA damage. Some subtle changes in this gene may impair repair efficiency and influence susceptibility to human cancers, including skin cancer. Two polymorphisms in XPC, 939A>C (rs2228001) and 499C>T (rs2228000), are considered to have possible associations with the risk of skin cancer, but the reported results have been inconsistent. Here we performed a meta-analysis of the available evidence regarding the relationship between these two polymorphisms and the risk of skin cancer. All relevant studies were searched using PubMed, Embase and Web of Science before February 2012. A total of 8 case-control studies were included in this analysis, and no convincing associations between the two polymorphisms and risk of skin cancer were observed in any of the genetic models. Stratified analyses by skin cancer type also did not detect significant associations in any subgroup. This meta-analysis suggested that the XPC 939A>C and 499C>T polymorphisms may have little involvement in susceptibility to skin cancer.
    Asian Pacific journal of cancer prevention: APJCP 10/2012; 13(10):4983-8. DOI:10.7314/APJCP.2012.13.10.4983 · 2.51 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The p53 gene is a critical molecular in the protection of cells from DNA damage due to Ultraviolet (UV) exposure, and TP53 mutation is very common in non-melanoma skin cancer. To assess the association between the TP53 Arg72Pro polymorphism and non-melanoma skin cancer (NMSC) risk. We performed this meta-analysis with 13 case-control studies involving 3,520 cases and 3,587 controls. Our meta-analysis showed that TP53 Arg72Pro polymorphism was not associated with non-melanoma skin cancer susceptibility in overall population.(for Arg/Arg vs. Pro/Pro: OR 0.98, 95% CI 0.80-1.19; for Arg/Pro vs. Pro/Pro: OR 0.99, 95% CI 0.84-1.17; for the recessive model Arg/Arg vs. Arg/Pro + Pro/Pro: OR 1.10, 95% CI 0.89-1.35; for the dominant model Arg/Arg + Arg/Pro vs. Pro/Pro: OR 1.00, 95% CI 0.85-1.18). We also detected no effect of this polymorphism on any subtype of non-melanoma skin cancer, such as squamous cell carcinoma (SCC), and basal cell carcinoma (BCC). Furthermore, no significant association in any subgroup was detected in stratified analyses according to ethnicity. However, in the stratified analysis by sample collection resources, Arg/Arg carriers from tumor tissue subgroup had 3.42 times risk of cancer (95% CI, 1.19 to 9.84) as compared with the variant type Pro/Pro in NMSC. TP53 Arg72Pro polymorphism may have little involvement in the pathogenesis of NMSC, regardless of type, including SCC, and BCC.
    Indian Journal of Dermatology 05/2013; 58(3):175-80. DOI:10.4103/0019-5154.110823
Show more

Similar Publications